Please assess the completion status of the following clinical trial:

Trial Title: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalization with moderate to severe COVID-19, defined as fulfilling at a minimum the following clinical status category on the WHO 8-point ordinal scale: (i) score 4 \[oxygen via mask or nasal\]~* Laboratory-confirmed SARS-CoV-2 infection at index hospitalisation as determined by PCR or other validated commercial or public health assay~* Bio-ADM ≥50 pg/mL or ≥30% increase until the end of the next day (with a minimum of 35 pg/mL at all)~* DPP3 ≤30 ng/mL~* Age ≥18 years at time of screening~* Body weight ≤ 150 kg at time of screening~Exclusion Criteria:~* Life expectancy less than 3 months before COVID-19 at the discretion of the Investigator~* Invasive mechanical ventilation ≥ 72 hours at time-point of randomization~* Resuscitation \> 45 minutes~* Hypersensitivity to the active substance, to Adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies~* Uncontrolled haematological/ oncological malignancies~* Pre-existing severe chronic liver disease (i.e. Child-Pugh C) before COVID-19 hospitalization~* Absolute neutropenia \<500 per μL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adrecizumab (HAM 8101) (Type: EXPERIMENTAL): Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 2 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
- Placebo/ control substance (NaCl 0.9%) (Type: PLACEBO_COMPARATOR): 100 mL saline as single dose infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).